Gene expression profiling has been conducted in rat hearts subjected to pressure overload (PO).
Introduction
Pressure and volume overload (PO and VO, respectively) produce morphologically and functionally distinct forms of cardiac hypertrophy (1) (2) (3) (4) ; PO produces concentric hypertrophy whereas VO produces eccentric hypertrophy. At the cellular level, cardiomyocytes grow vertically in PO and longitudinally in VO. The molecular mechanisms of these differences have been unknown. Changes of some specific genes have been reported in the hearts of PO and VO, i.e., the expressions of collagen isoforms (5, 6) and matrix metallo-proteinases (7), the expression of β myosin heavy chain (8) , the transcriptional regulation of adrenomedullin (9) , and the expressions of growth factors (10, 11) and β-tubulin (12) . Based on these previous reports, it is anticipated that some specific genes are regulated similarly or differentially in PO and VO, but the regulation of genes other than those listed above has not been clarified. Microarray analysis is a useful method to analyze the behavior of many genes. With this method, gene profiling has been conducted in animal hearts subjected to PO (13, 14) . Surprisingly, however, gene expression profiling has not been conducted in hearts subjected to VO. Accordingly, we compared the gene expression profiles in the hypertrophied myocardium of rats subjected to PO and VO using the DNA chip technology.
Methods

Animal Models
Male Wistar rats were used for the experiments. PO was produced in rats by abdominal aortic banding (15) , and VO by aortocaval shunting (16) . The rats were sacrificed 28 days after the procedure. All animal procedures were conducted according to the guidelines provided by the Kurume University Institutional Animal Care and Use Committee under an approved protocol.
Echocardiography
At the day before sacrifice, rats were lightly anesthetized with pentobarbital, then examined by echocardiography with an SSD 5500 and a 7.5 MHz probe (Aloka, Tokyo, Japan).
DNA Chip Analysis
DNA chips (GeneChip Rat Genome U34A arrays) were purchased from Affymetrix (Santa Clara, USA). Poly (A) RNA was extracted from the left ventricle (LV) by using a FAST track RNA purification kit (Invitrogen, Carlsbad, USA). We mixed poly (A) RNAs prepared from the LV of five rats and the samples were analyzed by three DNA chips in each group. DNA chip analysis was performed according to the manufacturer's recommended protocol. Each of the groups was compared with each of the other groups, resulting in 27 comparison tests. Average intensity values for each probe set were obtained from the Affymetrix MicroArray Suite 4.0. A p value less than 0.01 was arbitrarily assigned as the level of statistical significance. We considered genes that were elevated by > 2 fold compared with controls as "upregulated," genes that were reduced to < 0.5 as "downregulated," and genes that were altered by 0.8-1.2 fold as showing "no change." The genes that were expressed at very low levels (those with a signal intensity less than 100) or genes that were considered not to be present based on low signal intensity by the Affymetrix software under all conditions were omitted.
For clustering analysis, the CEL files were converted into DCP files using dCHIP analysis software (www.biostat.har vard.edu/compalab/cdhip/), as described previously by Li and Wong (17) . Genechips were normalized, and model-based expression values were generated. We used hierarchical clus- tering with the average linkage method. The functions of these altered genes were classified by clusters of orthologous groups analysis.
Fig. 1. Echocardiographic measurements of the hypertrophied rat heart. Echocardiography was performed 28 days after hemodynamic overload as described in
Real-Time Reverse Transcription-Polymerase Chain Reaction
Total RNA was prepared with an RNeasy Midi Kit (QIAGEN, Tokyo, Japan) from LV. Real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed by a GeneAmp 5700 and a TaqMan One-Step RT-PCR Master Mix Reagents Kit (Applied Biosystems, Foster City, USA) according to the manufacturer's instruction. Expression values for each gene were normalized to 18 S ribosomal RNA (TaqMan ribosomal RNA control reagents; Applied Biosystems). The primers and TaqMan probes used in these experiments were as follows: guanosine monophosphate (GMP) reductase TaqMan probe, CTCTGACGG AAGCTGCACATGTCCA; GMP reductase sense-primer, GGCCTCAAGGGACACATCA; GMP reductase antisenseprimer, AAAGGCTTTGGCGACATCTC; metallothionein-1 (MT) TaqMan probe, TGCAAAGGTGCCTCGGACAAG TGC; MT sense-primer, GTGGGCTGCTCCAAATGTG; MT antisense-primer, GGTCCGGAAATTATTTACACC TGA; B-type natriuretic peptide (BNP) TaqMan Probe, CGGCGCAGTCAGTCGCTTGG; BNP sense-primer, TGG GCAGAAGATAGACCGGA; BNP antisense-primer, ACA ACCTCAGCCCGTCACAG; lysyl oxidase-like protein 1 
Subcloning of Rat MT
Rat MT cDNA was cloned from rat heart by RT-PCR. The following primers were used for this experiment: sense primer, 5′-ACTGCCTTCTTGTCGCTTAC-3′; antisense primer, 5′-AGGGCAGCAGCACTGTTCGT-3′. This PCR product was subcloned into pCR2.1 and then transferred to pcDNA 3.1 (Invitrogen).
Cell Culture and Transfection
H9c2 cells (a cardiac myoblast cell line) were obtained from the American Type Culture Collection (Rockville, USA). Cells were transfected with rat MT-pcDNA3.1 or pcDNA 3.1 (empty vector) by Lipofectamine 2000 (Amersham Biosciences, Piscataway, USA). At 24 h after the transfection, cells were exposed to norepinephrine (NE; 10 −4 mol/l) and cultured for an additional 24 h. The efficiency of the transfection was assessed by the co-transfection of pQBI50, which encodes blue fluorescent protein (Takara, Tokyo, Japan).
Assessment of Apoptosis and Caspase 3 Assay
Apoptosis was assessed by TUNEL staining (In Situ Cell Death Detection kit, Roche Diagnostics, Mannheim, Germany). Caspase-3 activity was measured by a CaspACE assay system (Promega, Madison, USA).
Statistical Analysis
Data are presented as the mean±SEM. Comparisons of mean values were performed by one-way ANOVA followed by Scheffe's test. Values of p< 0.05 were considered to indicate statistically significant differences. Figure 1 shows the echocardiographic findings 4 weeks after the surgery. Left ventricular diastolic diameter (LVDd) was significantly higher in the rats subjected to VO compared with those subjected to PO and those undergoing sham operation (hereafter the VO, PO, and sham groups, respectively) (PO: 96 ±8% of the sham-group value; VO: 119±9% of the sham-group value). While interventricular septal wall thickness (IVST) was increased in both types of hypertrophy (PO, 126±12% of the sham-group value; VO, 120±11% of the sham-group value), the IVST of the PO group was greater than that of the VO group. Thus, PO produced concentric hypertrophy and VO produced eccentric hypertrophy. There was no difference among the PO, VO and sham groups in percent fractional shortening (%FS). The left atrial diameter (LAD) of both hypertrophy groups was larger than that of the sham group. As shown in Fig. 2 , the left ventricular weight/ body weight ratio and heart weight/body weight ratio were significantly increased in both hypertrophy groups, compared with the sham group. These ratios were slightly larger in the VO than the PO group (PO: 139±11% of the sham-group value; VO: 157±16% of the sham-group value). Figure 3 and Table 1 show results of DNA chip analysis. A total of 33 genes were upregulated in both forms of hypertrophy, whereas 31 were downregulated. The genes that were upregulated in both forms included BNP, atrial natriuretic peptide (ANP), and skeletal α-actin, which are known to be upregulated in the hypertrophied myocardium. In the PO group, 52 genes were selectively upregulated and 41 genes were downregulated. In the VO group, 88 genes were selectively upregulated and 46 genes were downregulated.
Results
Subsequently, we performed hierarchical clustering with the average linkage method. Figure 4 shows the cluster of upregulated genes (A) and downregulated genes (B) in both hypertrophy groups. The differentially expressed genes were grouped by functional category classification according to the GeneOntology (http://www.geneontology.org/) terms based on the NCBI LocusLink (http://www.ncbi.nlm.nih.gov/ LocusLink/) database. The gene cluster that showed the most marked increase was the natriuretic peptide family. The hydrogen-transporting two-sector ATPase group, the cytoskeletal organization and biogenesis group, and the mitochondrial substrate carrier group were upregulated in both hypertrophied hearts. On the other hand, the calcium ionbinding group and the basic-leucine zipper transcription factor group were downregulated in both hypertrophy groups. We observed selective upregulation of the genes that bind to actin in the VO group (e.g., tropomyosin 4, thymosin β-4, and transgelin).
Next, we performed real-time RT-PCR analysis to confirm the results of the DNA chip analysis (Fig. 5) . Real-time RT-PCR revealed that BNP, MT and LOXL mRNAs were all upregulated in both the VO and PO groups, compared with the sham group. MT mRNA expression in the VO group was significantly higher than that in the PO group. The levels of BNP and LOXL mRNAs in the VO group were also higher than those in the PO group, but these differences did not reach the level of statistical significance. DNA chip analysis showed that GMP reductase mRNA was selectively downregulated in the VO group. This was confirmed by real-time RT-PCR.
We then examined the expressions of some of the genes that were differentially altered in VO and PO hearts. DNA chip analysis revealed that transgelin was increased in the VO group but downregulated in the PO group, and PDK1 was decreased in VO but upregulated in PO. Real-time RT-PCR confirmed these changes (Fig. 5E, F) .
In our DNA chip analysis, BNP and ANP showed the most remarkable upregulations in hypertrophied LVs. MT showed the next highest level of upregulation. Accordingly, we examined the role of MT in the development of cardiac hypertrophy (Fig. 6 ). MT is a free radical scavenger and is suggested to play a protective role in many cell types. Therefore, we hypothesized that MT plays an anti-apoptotic role in cardiac hypertrophy and performed the following experiments. MT cDNA or control vector (pcDNA3.1) was overexpressed in H9c2 cells. The cells were then exposed to a high concentration of NE for 24 h, and TUNEL staining was performed. In cells overexpressing the control vector, NE increased TUNEL-positive cells. Overexpression of MT inhibited the increase of TUNEL-positive cells (Fig. 6) . To confirm the anti-apoptotic effects of MT, we next examined the level of caspase-3 activity, which is critically involved in apoptosis, in these cells (Fig. 7) . Caspase-3 activity was increased in cells treated with NE. The overexpression of MT reduced the augmentation of caspase-3 activity by 42±9.9% compared with that in the cells transfected with the control vector (pCDNA3.1; Fig. 7 ).
Discussion
We examined the similarity and difference of the gene expression profiling between the PO and VO hearts. We found many genes that are regulated similarly or differentially between the two groups. The alterations of some specific genes were confirmed by real-time RT-PCR. Among the genes that were upregulated in both forms of hypertrophy, we examined the role of MT in apoptosis, and found that this gene played a novel role in anti-apoptosis. 
Methodological Considerations
In this study, we used two different procedures to induce cardiac hypertrophy: abdominal constriction for pressure overload and aortocaval shunt for volume overload. These two procedures produced the same magnitude of hypertrophy with distinct morphological differences as shown by echocardiography. Thus the similarities in gene profiling may be attributable to hypertrophy per se and the dissimilarity to the different morphologies of the heart, i.e., concentric hypertrophy or eccentric hypertrophy. In both forms of hypertrophy, cardiac function assessed by fractional shortening was normal, indicating that changes in gene profiling were not attributable to those of the myocardium at the failing stage.
These mechanical stresses activate many molecules in the heart. There are two peaks in the activations of biochemical signals after an exposure to hemodynamic load (18) . Acute responses occur within a few minutes, and hypertrophic responses follow over the next several days or weeks. As a pilot study, we measured the time-dependent change of the expression of BNP mRNA in rat PO hearts. The left ventricular weight/body weight ratio increased gradually until day 28 after the initiation of PO and continued at a plateau level thereafter. BNP mRNA levels showed a biphasic response, i.e., an initial increase and a later gradual increase. The first peak of the expression was at 24 h and the subsequent peak was at day 28 (data not shown). Thus, at day 28 acute gene responses were no longer observed and hypertrophic gene responses were maximal and stable. This is the time when hypertrophy was morphologically established. In order to investigate gene responses with hypertrophy but without heart failure, we chose day 28.
We examined gene profiling at the stage of established cardiac hypertrophy but did not examine it chronologically. Thus the gene profiling in our study may not represent that of the developmental stage of hypertrophy, but merely that of the compensation of hypertrophy. Moreover, we examined gene profiling of the whole heart. Thus our results do not necessarily indicate gene profiling of cardiomyocytes, but may also include profiling for the interstitial tissues.
Gene Profiling in PO and VO
The present study revealed gene expression profiles that may be associated with hypertrophy per se or different types of remodeling. In agreement with previous reports (13, 14, 19, 20) , we found changes in gene profiling in PO. As shown in Fig. 3 , most genes were unaltered in the hypertrophic myocardium induced by PO. Only 85 genes were upregulated. Thus, the number of genes upregulated in the hypertrophied myocardium induced by PO was less than that of several previous reports. This discrepancy may be ascribable to the criteria used for the gene selection and the use of different kinds of chips. The present study is the first to describe gene expressions in VO. As shown in Fig. 3 and Table 1 , the levels of most of the genes were unaltered, just as in PO. Only 121 genes were upregulated. It may be interesting to note that some genes were regulated differentially between VO and PO. Among those genes, extracellular matrix-related proteins, e.g., osteopontin, secreted acidic cysteine rich glycoprotein, and tropoelastin, were predominantly upregulated in VO. The upregulation of these genes may be related to the specific remodeling in VO, but not to hypertrophy per se. In addition, the selective upregulation of genes in VO that bind to actin (e.g., tropomyosin 4, thymosin β-4, and transgelin) may explain the difference in structural ventricular remodeling between VO and PO. Several gene profiles have been reported in other models of hypertrophy (21, 22) . These reports have shown that the common genetic events in hypertrophy include upregulations of ANP, BNP, and skeletal α-actin. These genes were increased in both forms of hypertrophy in the present study as well.
GMP reductase was predominantly downregulated in VO. Because GMP reductase increases the adenine nucleotide pool through synthesis of inosine monophosphate (23), the decrease of GMP reductase may have some deteriorative effects on myocardial metabolism. We also found that the expressions of PDK-1 and transgelin were differentially regulated in VO and PO hearts (Fig. 5E, F) . Transgelin (also known as SM22 α) is a 22-kDa protein that is associated with cytoskeletal actin filament bundles in contractile smooth muscle cell (SMC) (24, 25) . It is expressed in cardiac, smooth, and skeletal muscle cells during early embryogenesis but becomes restricted to visceral and vascular SMC at late embryonic stages and throughout adulthood. Transgelin was upregulated in VO and downregulated in PO hearts in the (Fig. 5E ), but the significance of these changes is unknown. Transgelin may regulate several genes that are associated with vascular development, remodeling, and alterations. The differential expression of this gene may reflect the difference of vascular remodeling between concentric and eccentric cardiac hypertrophy. PDK-1 was downregulated in VO but upregulated in PO (Fig. 5F ). PDKs phosphorylate the mitochondrial pyruvate dehydrogenase complex, which catalyzes the oxidative decarboxylation of pyruvate, and thereby inactivate it (26) . Although the significance of alterations of this enzyme in the hypertrophied hearts is unclear, these changes may be associated with the difference of the myocardial energy production in both forms of hypertrophy.
Upregulated Genes in Both Forms of Hypertrophy
Our DNA chip analysis showed upregulation of 33 genes in both forms hypertrophy (Table 1) . These genes may be associated with hypertrophy per se. Among these genes, we confirmed the upregulations of BNP, MT and LOXL mRNA. Wang et al. (13) and Weinberg et al. (14) have reported that MT is upregulated significantly in aortic banding mice. In the present study, MT was one of genes showing the highest level of upregulation in both forms of hypertrophied heart. Accordingly, we examined the role of MT in cardiac hypertrophy. MT is a cysteine-rich protein with a strong affinity for Zn 2+ (reviewed in Palmitter (27) , and Kang (28)). MT is known to detoxify the heavy metals. Recent studies revealed that MT binds to rare metals in vivo and regulates metalprotein and metal-dependent transcriptional factors. Moreover, MT is a potent free radical scavenger. And in the hearts of mice with adriamycin-induced cardiomyopathy, MT expression has been shown to be increased (29) . Moreover, it has been reported that overexpression of MT in the hearts of transgenic mice suppresses doxorubicin cardiotoxicity and ischemiareperfusion injury (30, 31) . Thus MT plays cytoprotective roles in many cell types. In this study, MT suppressed the NEinduced increase of TUNEL-positive cells. This inhibition was associated with the suppression of caspase-3 activity, suggesting that MT inhibits the apoptosis of cardiomyocytes. It has been reported that the myocardium of both rat models of hypertrophy shows apoptotic cardiomyocyte death (32, 33) . Therefore, we consider that MT may exert anti-apoptotic effects under physiological conditions. Aronow and coworkers showed that MT was universally increased in hypertrophied hearts produced by four different mechanisms, suggesting that the upregulation of MT is a highly conserved genetic event in hypertrophy (21) . Interestingly, the expression of MT was greater in the hypertrophy model than in the heart failure model in their study (21) . This suggests that apoptosis of the hypertrophied myocardium, which leads to heart failure, is prevented by the expression of MT. Taken together, these findings indicate that MT may have a protective effect on the heart through its anti-apoptotic effects.
LOXL was also significantly upregulated in both forms of hypertrophy. LOXL is a member of the lysyl oxidase gene family, which is an extracellular, copper-dependent enzyme family that initiates the cross-linking of collagens and elastin (34, 35) . It may be possible that LOXL is associated with the remodeling of the extracellular matrix in the hypertrophied myocardium. Among the upregulated genes, GATA-4 is known to be essential for the induction of several cardiac-specific genes (36) . The upregulation of GATA-4 supports the idea that this protein may be the common regulator of hypertrophic responses.
In conclusion, we found many genes that are similarly or dissimilarly regulated in the hearts of VO and PO. The altered expressions of BNP, MT, GMP reductase, LOXL, transgelin, and PDK-1 were confirmed by real-time RT-PCR. Gene profiling by DNA chip technology represents a useful tool for identification of genes that may contribute to morphological and functional differences between PO and VO. Moreover, the overexpression of MT in H9c2 cells attenuated the norepinephrine-induced apoptosis. MT may play a novel protective role in the development of cardiac hypertrophy. Although we found that many genes were altered in the hypertrophied hearts, it remains uncertain whether these changes played a role in or were secondary to the development of hypertrophy. To clarify these questions, functional studies should be performed for each molecule.
